Phase II ADAPT Trial in Patients With HER2+ and HR+ Early Breast Cancer

Video

Douglas Yee, MD, professor of medicine and pharmacology, Hematology, Oncology and Transplantation, Department of Medicine, medical oncologist, University of Minnesota, discusses the results of the phase II ADAPT trial.

Yee describes how the clinical trial evaluated the triple positive subgroup of women, with an endpoint of pathologic complete response. The rate was high for both T-DM1 and the addition of endocrine therapy. However, the rate was very low for the combination of trastuzumab and endocrine therapy.

Douglas Yee, MD, professor of medicine and pharmacology, hematology, oncology and transplantation, Department of Medicine, medical oncologist, University of Minnesota, discusses the results of the phase II ADAPT trial. It showed promise for chemotherapy-free neoadjuvant treatment with T-DM1 in patients who have HER2+ and HR+ early breast cancer.

Related Videos
Video 3 - "Managing Toxicities and Adverse Reactions in HR+/Her2-Low mBC Therapies"
Video 2 - "EMERALD: Underscoring Key Elacestrant Data + Subgroup Analyses for Informed Therapy Selection"
Video 1 - "A 62-Year-Old Woman with HR+ HER2-low Metastatic Breast Cancer and Lung, Liver, and Bone Metastases and Using Biomarker Testing to Guide Treatment Selection"
Related Content